Synthesis and Anti-Cancer Activity In Vitro of Synephrine Derivatives

Overview

Journal Biomolecules

Publisher MDPI

Date 2025 Jan 25

PMID 39858397

Authors

Ekaterina M Zhidkova

Evgeniya S Oleynik

Ekaterina A Mikhina

Daria V Stepanycheva

Diana D Grigoreva

Lyubov E Grebenkina

Kirill V Gordeev

Ekaterina D Savina

Andrey V Matveev

Marianna G Yakubovskaya

Ekaterina A Lesovaya

Affiliations

Soon will be listed here.

Abstract

Glucocorticoids (GCs) are routinely used to treat hematological malignancies; however, long-term treatment with GCs can lead to atrophic and metabolic adverse effects. Selective glucocorticoid receptor agonists (SEGRAs) with reduced side effects may act as a superior alternative to GCs. More than 30 SEGRAs have been described so far, yet none of them reached clinical trials for anti-cancer treatment. In the present work, we propose a novel approach to increase the number of potential SEGRAs by obtaining derivatives of synephrine, a molecule of natural origin. We synthesized 26 novel compounds from the class of synephrine derivatives and characterized them by HRMS, and H and C NMR. We evaluated anti-cancer effects in leukemia K562 and lymphoma Granta cells using the MTT assay and studied their potential affinity for the glucocorticoid receptor (GR) using the molecular docking approach. The novel derivative 1-[4-(benzyloxy)phenyl]-2-(hexylamino)ethanol () with the highest GR affinity exhibited cytotoxic activity against K562 and Granta cells after 24 h of treatment at the concentration of approximately 13 µM which correlated with its highest MolDock Score. The other compound with high GR affinity, 2-(hexylamino)-1-(4-nitrophenyl)ethanol (), demonstrated cytotoxicity in both cell lines at concentrations of 50-70 µM. Overall, our results may provide a solid rationale for developing and further investigating synephrine derivatives as SEGRAs with anti-cancer activity.

References

Eiers A, Vettorazzi S, Tuckermann J . Journey through discovery of 75 years glucocorticoids: evolution of our knowledge of glucocorticoid receptor mechanisms in rheumatic diseases. Ann Rheum Dis. 2024; 83(12):1603-1613. DOI: 10.1136/ard-2023-225371. View

McConkey D, Zhu K . Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat. 2008; 11(4-5):164-79. DOI: 10.1016/j.drup.2008.08.002. View

Lesovaya E, Yemelyanov A, Swart A, Swart P, Haegeman G, Budunova I . Discovery of Compound A--a selective activator of the glucocorticoid receptor with anti-inflammatory and anti-cancer activity. Oncotarget. 2015; 6(31):30730-44. PMC: 4741564. DOI: 10.18632/oncotarget.5078. View

Lesovaya E, Yemelyanov A, Kirsanov K, Popa A, Belitsky G, Yakubovskaya M . Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies. Cell Cycle. 2012; 12(1):133-44. PMC: 3570502. DOI: 10.4161/cc.23048. View

Ishida M, Takekuni C, Nishi K, Sugahara T . -Synephrine suppresses inflammatory responses in lipopolysaccharide-stimulated RAW264.7 cells and alleviates systemic inflammatory response syndrome in mice. Food Funct. 2022; 13(9):5229-5239. DOI: 10.1039/d2fo00299j. View

Zhidkova E, Tilova L, Fetisov T, Kirsanov K, Kulikov E, Enikeev A . Synthesis and Anti-Cancer Activity of the Novel Selective Glucocorticoid Receptor Agonists of the Phenylethanolamine Series. Int J Mol Sci. 2024; 25(16). PMC: 11354514. DOI: 10.3390/ijms25168904. View

Roman G, Vlahakis J, Vukomanovic D, Nakatsu K, Szarek W . Heme oxygenase inhibition by 1-aryl-2-(1h-imidazol-1-yl/1h-1,2,4-triazol-1-yl)ethanones and their derivatives. ChemMedChem. 2010; 5(9):1541-55. DOI: 10.1002/cmdc.201000120. View

Dodonova S, Zhidkova E, Kryukov A, Valiev T, Kirsanov K, Kulikov E . Synephrine and Its Derivative Compound A: Common and Specific Biological Effects. Int J Mol Sci. 2023; 24(24). PMC: 10744207. DOI: 10.3390/ijms242417537. View

Jin S, Seo C, Jeon W, Oh Y, Shin H, Jeong H . Evodiae Fructus extract suppresses inflammatory response in HaCaT cells and improves house dust mite-induced atopic dermatitis in NC/Nga mice. Sci Rep. 2024; 14(1):472. PMC: 10764943. DOI: 10.1038/s41598-023-50257-3. View

10.

Zare F, Solhjoo A, Sadeghpour H, Sakhteman A, Dehshahri A . Structure-based virtual screening, molecular docking, molecular dynamics simulation and MM/PBSA calculations towards identification of steroidal and non-steroidal selective glucocorticoid receptor modulators. J Biomol Struct Dyn. 2022; 41(16):7640-7650. DOI: 10.1080/07391102.2022.2123392. View

11.

De Bosscher K . Selective Glucocorticoid Receptor modulators. J Steroid Biochem Mol Biol. 2010; 120(2-3):96-104. DOI: 10.1016/j.jsbmb.2010.02.027. View

12.

Lesovaya E, Yemelyanov A, Kirsanov K, Yakubovskaya M, Budunova I . Antitumor effect of non-steroid glucocorticoid receptor ligand CpdA on leukemia cell lines CEM and K562. Biochemistry (Mosc). 2011; 76(11):1242-52. DOI: 10.1134/S000629791111006X. View

13.

Gottlieb H, Kotlyar V, Nudelman A . NMR Chemical Shifts of Common Laboratory Solvents as Trace Impurities. J Org Chem. 2001; 62(21):7512-7515. DOI: 10.1021/jo971176v. View

14.

Lesovaya E, Savinkova A, Morozova O, Lylova E, Zhidkova E, Kulikov E . A Novel Approach to Safer Glucocorticoid Receptor-Targeted Anti-lymphoma Therapy via REDD1 (Regulated in Development and DNA Damage 1) Inhibition. Mol Cancer Ther. 2020; 19(9):1898-1908. PMC: 7875139. DOI: 10.1158/1535-7163.MCT-19-1111. View

15.

Desmet S, Bougarne N, Van Moortel L, De Cauwer L, Thommis J, Vuylsteke M . Compound A influences gene regulation of the Dexamethasone-activated glucocorticoid receptor by alternative cofactor recruitment. Sci Rep. 2017; 7(1):8063. PMC: 5556032. DOI: 10.1038/s41598-017-07941-y. View

16.

Xu W, Zheng C, Huang Y, Chen W, Yang Q, Ren J . Synephrine Hydrochloride Suppresses Esophageal Cancer Tumor Growth and Metastatic Potential through Inhibition of Galectin-3-AKT/ERK Signaling. J Agric Food Chem. 2018; 66(35):9248-9258. DOI: 10.1021/acs.jafc.8b04020. View

17.

Saglio G, Sharf G, Almeida A, Bogdanovic A, Bombaci F, cugurovic J . Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient-Physician Perspective. Clin Lymphoma Myeloma Leuk. 2018; 18(6):375-379. DOI: 10.1016/j.clml.2018.04.005. View

18.

Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C . Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood. 2011; 118(22):5752-8. DOI: 10.1182/blood-2011-05-355081. View

19.

Lesovaya E, Chudakova D, Baida G, Zhidkova E, Kirsanov K, Yakubovskaya M . The long winding road to the safer glucocorticoid receptor (GR) targeting therapies. Oncotarget. 2022; 13:408-424. PMC: 8858080. DOI: 10.18632/oncotarget.28191. View

20.

Wang Y, Lin S, Wang Y, Liang T, Jiang T, Liu P . -Synephrine ameliorates alloxan-induced diabetes mellitus through inhibiting oxidative stress and inflammation suppressing the NF-kappa B and MAPK pathways. Food Funct. 2023; 14(4):1971-1988. DOI: 10.1039/d2fo03003a. View